B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas [Phase 1]
A Phase 1 trial is evaluating the safety of REGN5837 in combination with odronextamab for adults with aggressive B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL [Phase 1, Phase 2]
This clinical trials update describes a phase 1/2 study of a CD19 CAR T-cell therapy with CD34 selection for patients with CD19-positive rel…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
An active clinical trial investigates dynamic monitoring of plasma circulating tumor DNA to prognosticate outcomes in patients with B-cell n…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating PIT565 in relapsed/refractory B-cell malignancies, including B-cell Non-Hodgkin Lymphoma and B-cell Acute Lymphobla…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL [Phase 2]
A Phase II trial is evaluating a four-drug combination (mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide) in relapsed B-cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update on the investigational drug GLPG5101 (19CP02) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, with th…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial by ImmunityBio for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) [Phase 1]
This clinical trial update describes an ongoing Phase 1 study evaluating loncastuximab tesirine in combination with other anticancer agents …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL [Phase 1]
This clinical trial update describes a Phase 1 study of GB5005 CART-cell injection targeting CD19 in patients with relapsed or refractory B-…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating CD19/CD22 bicistronic CAR T cells in children and young adults with recurrent or refractory CD19/CD…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 trial update for ATA3219 in relapsed/refractory B-cell non-Hodgkin lymphoma notes that the study has been terminated, with safety …
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CMV-specific CD19-CAR T-cells in combination with the CMV-MVA Triplex vaccine for intermediate- or high-…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: CD45BE-HSPC + CART-45 Cells [Phase 1]
Phase 1 study evaluating CD45BE-HSPC with CART-45 cells is not yet recruiting and targets B-cell non-Hodgkin lymphoma and Richter transforma…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) [Phase 1]
Phase 1 trial update for a CD19-targeted CAR T cell therapy in pediatric patients with relapsed or refractory B cell acute lymphoblastic leu…
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Roche is conducting a Phase 1/2 trial to evaluate Englumafusp Alfa in combination with Obinutuzumab and in combination with Glofitamab after…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-ce…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study of TORL-5-700 is evaluating its safety and early efficacy in relapsed or refractory B-cell non-Hodgkin lymphoma; the trial…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL [Phase 2]
A Phase 2 clinical trial examining Surovatamig (AZD0486) as monotherapy in relapsed/refractory B-cell non-Hodgkin lymphoma, including follic…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial from City of Hope evaluating CMV-specific CD19-CAR T-cells with CMV-MVA Triplex vaccine after stem cell transplantati…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma [Phase 2, Phase 3]
Global pediatric/adolescent trial evaluating novel agents for relapsed and refractory B-cell non-Hodgkin lymphoma. The study is currently re…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma [Phase 2]
Valemetostat tosylate is being studied as a single-agent therapy for relapse or refractory B-cell lymphoma in a Phase 2 trial, which is curr…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial update from Northwestern University evaluating the combination of epcoritamab and lenalidomide in patients with refractory o…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients [Phase 3]
A Phase 3 intergroup trial evaluating rituximab in high-risk pediatric patients with B-cell non-Hodgkin lymphoma or Burkitt leukemia has com…